Patently Innovative

<p>Dedication</p> <p>Acknowledgements</p> <p>List of figures and tables</p> <p>List of abbreviations</p> <p>About the author</p> <p>Chapter 1: Introduction</p> <p>Abstract:</p> <p>1.1 The emergence of global pharmaceutical linkage</p> <p>1.2 Canadian pharmaceutical linkage regulations</p> <p>1.3 Organization</p> <p>Chapter 2: Background: drug approval, drug patenting, pharmaceutical linkage, and public health policy</p> <p>Abstract:</p> <p>2.1 Drug approval</p> <p>2.2 Patents</p> <p>2.3 Linkage regulations</p> <p>2.4 IPR rights and innovation policy</p> <p>Chapter 3: Empirical analysis of drug approval</p> <p>Abstract:</p> <p>3.1 Introduction</p> <p>3.2 Analysis</p> <p>3.3 Results</p> <p>3.4 Discussion</p> <p>3.5 Interpretation of data</p> <p>3.6 Study limitations</p> <p>3.7 Assessing the lifecycle approach: the long view</p> <p>3.8 Government as representative public agent</p> <p>3.9 Summary and conclusions</p> <p>Chapter 4: Empirical analysis of pharmaceutical innovation and drug approval-drug patenting linkage</p> <p>Abstract:</p> <p>4.1 Introduction</p> <p>4.2 Methods</p> <p>4.3 Results</p> <p>4.4 Discussion</p> <p>Chapter 5: Empirical analysis of drug patenting in multiple high-value cohorts</p> <p>Abstract:</p> <p>5.1 Introduction</p> <p>5.2 Methods</p> <p>5.3 Results</p> <p>5.4 Discussion</p> <p>5.5 Summary and conclusions</p> <p>Chapter 6: Implications of empirical data: are pharmaceutical linkage regulations a success?</p> <p>Abstract:</p> <p>6.1 Introduction</p> <p>6.2 Debate preceding Bill C-91</p> <p>6.3 ‘Original policy intent’</p> <p>6.4 ‘Patent-specific’ analysis</p> <p>6.5 Statutory interpretation</p> <p>6.6 Revisiting the empirical data</p> <p>6.7 Summary and conclusions</p> <p>Chapter 7: Future directions: testable hypotheses and evolution toward global pharmaceutical linkage</p> <p>Abstract:</p> <p>7.1 Hypotheses regarding cluster-based drug development</p> <p>7.2 Globalization of pharmaceutical linkage</p> <p>Index</p>